ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 32932925

Recent Progress in the Systemic Treatment of Advanced/Metastatic Cholangiocarcinoma.

Fostea RM and 3 others. Cancers (Basel), 2020. Cited by 32 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Recent Progress in the Systemic Treatment of Advanced/Metastatic Cholangiocarcinoma. Papers, record 32932925. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32932925

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Recent Progress in the Systemic Treatment of Advanced/Metastatic Cholangiocarcinoma.
PubMed
Journal
Cancers (Basel)
PubMed
Year
2020
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
32
iCite
Relative citation ratio, by iCite
1.58
iCite
Revised in PubMed
2024-08-02
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Fostea RMRaluca Maria
2Fontana EElisahttps://orcid.org/0000-0002-4991-9355
3Torga GGonzalohttps://orcid.org/0000-0002-6401-5127
4Arkenau HTHendrik-Tobiashttps://orcid.org/0000-0002-2015-1549

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References38

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
126,258,846Genomic spectra of biliary tract cancer.Nat Genet2015https://conductscience.org/library/papers/26258846PubMed
232,416,072Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.Lancet Oncol2020https://conductscience.org/library/papers/32416072PubMed
324,423,918S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.Br J Cancer2014https://conductscience.org/library/papers/24423918PubMed
431,949,927Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers.J Gastrointest Oncol2019https://conductscience.org/library/papers/31949927PubMed
531,765,263Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study.J Clin Oncol2020https://conductscience.org/library/papers/31765263PubMed
628,818,953New Horizons for Precision Medicine in Biliary Tract Cancers.Cancer Discov2017https://conductscience.org/library/papers/28818953PubMed
732,622,884Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors.Ann Oncol2020https://conductscience.org/library/papers/32622884PubMed
832,203,698Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.Lancet Oncol2020https://conductscience.org/library/papers/32203698PubMed
932,472,305Pemigatinib: First Approval.Drugs2020https://conductscience.org/library/papers/32472305PubMed
1032,487,595Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow.Anticancer Res2020https://conductscience.org/library/papers/32487595PubMed

1 to 10 of 38

See all 38 references

Cited by23

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 32 citations.

PMIDTitleJournalYearIn PapersSource
39,959,690Abdominal Bloating Following a Diagnosis of Aplastic Anemia: Correlation or Red Herring?J Adv Pract Oncol2025https://conductscience.org/library/papers/39959690PubMed
39,660,136Research hotspots and trends in immunotherapy for cholangiocarcinoma: a bibliometric analysis (2014-2023).Front Immunol2024https://conductscience.org/library/papers/39660136PubMed
38,553,250Determination of copper and other trace elements in serum samples from patients with biliary tract cancers: prospective noninterventional nonrandomized clinical study protocol.Radiol Oncol2024https://conductscience.org/library/papers/38553250PubMed
38,274,721Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line, ICC-X2.World J Oncol2024https://conductscience.org/library/papers/38274721PubMed
36,647,192Curcumin analog WZ26 induces ROS and cell death via inhibition of STAT3 in cholangiocarcinoma.Cancer Biol Ther2023https://conductscience.org/library/papers/36647192PubMed
36,537,386Efficacy of EUS-guided hepaticogastrostomy in prolonging survival of patients with perihilar cholangiocarcinoma.Endosc Ultrasound2022https://conductscience.org/library/papers/36537386PubMed
36,497,187FGFR Inhibitors in Cholangiocarcinoma-A Novel Yet Primary Approach: Where Do We Stand Now and Where to Head Next in Targeting This Axis?Cells2022https://conductscience.org/library/papers/36497187PubMed
36,381,099Sarcomatoid Intrahepatic Cholangiocarcinoma After Immunotherapy: A Case Report and Review of the Literature.J Clin Transl Hepatol2022https://conductscience.org/library/papers/36381099PubMed
36,038,334[Emphasis on the treatment of biliary liver disease].Zhonghua Gan Zang Bing Za Zhi2022https://conductscience.org/library/papers/36038334PubMed
35,807,269Novel Nitric Oxide Donor Dinitroazetidine-Coumarin Hybrids as Potent Anti-Intrahepatic Cholangiocarcinoma Agents.Molecules2022https://conductscience.org/library/papers/35807269PubMed

1 to 10 of 23

See all 23 cited by

Genes39

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ARID1A8,289PubTator's text mininghttps://conductscience.org/library/genes/8289NCBI Gene
ATM472PubTator's text mininghttps://conductscience.org/library/genes/472NCBI Gene
BAP18,314PubTator's text mininghttps://conductscience.org/library/genes/8314NCBI Gene
BRAF673PubTator's text mininghttps://conductscience.org/library/genes/673NCBI Gene
BRCA1672PubTator's text mininghttps://conductscience.org/library/genes/672NCBI Gene
BRCA2675PubTator's text mininghttps://conductscience.org/library/genes/675NCBI Gene
CD27429,126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
CDKN2A1,029PubTator's text mininghttps://conductscience.org/library/genes/1029NCBI Gene

1 to 10 of 39

See all 39 genes

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32932925

GET https://conductscience.org/api/papers/v1/32932925/references?page=2

API referenceFor AI assistants